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Abstract: Human serum albumin (HSA) is the most abundant human plasma protein. HSA plays a
crucial role in many binding endos- and exogenous substances, which affects their pharmacological
effect. The innovative aspect of the study is not only the interaction of fatted (HSA) and defatted
(dHSA) human serum albumin with ibuprofen (IBU), but the analysis of the influence of temperature
on the structural modifications of albumin and the interaction between the drug and proteins from
the temperature characteristic of near hypothermia (308 K) to the temperature reflecting inflammation
in the body (312 K and 314 K). Ibuprofen is a non-steroidal anti-inflammatory drug. IBU is used to
relieve acute pain, inflammation, and fever. To determine ibuprofen’s binding site in the tertiary
structure of HSA and dHSA, fluorescence spectroscopy was used. On its basis, the fluorescent
emissive spectra of albumin (5 × 10−6 mol/dm3) without and with the presence of ibuprofen
(1 × 10−5–1 × 10−4 mol/dm3) was recorded. The IBU-HSA complex’s fluorescence was excited by
radiation of wavelengths of λex 275 nm and λex 295 nm. Spectrophotometric spectroscopy allowed
for recording the absorbance spectra (zero-order and second derivative absorption spectra) of HSA
and dHSA under the influence of ibuprofen (1 × 10−4 mol/dm3). To characterize the changes of
albumin structure the presence of IBU, circular dichroism was used. The data obtained show that the
presence of fatty acids and human serum albumin temperature influences the strength and type of
interaction between serum albumin and drug. Ibuprofen binds more strongly to defatted human
serum albumin than to albumin in the presence of fatty acids. Additionally, stronger complexes
are formed with increasing temperatures. The competitive binding of ibuprofen and fatty acids to
albumin may influence the concentration of free drug fraction and thus its therapeutic effect.
Keywords: human serum albumin; ibuprofen; spectrophotometric; spectrofluorometric; circu-
lar dichroism
1. Introduction
Serum albumin is the most frequently occurring protein in blood plasma [1–3]. A stan-
dard concentration of albumin in plasma is in the range of 35–45 g/L [4,5]. Human serum
albumin (HSA) forms a heart-shaped molecule consist of 585 amino acid residues. HSA is
characterized by a high cysteine content and low tryptophan content [1,4–6]. Crystal struc-
ture analysis of human serum albumin revealed that HSA contains three homologous
domains (I–III). All domains are divided into two subdomains A and B, composed of four
and six α-helices [1,6]. Human serum albumin exhibits the ability to bind many endogenous
and exogenous ligands such as drugs, fatty acids, amino acids, hormones, vitamins [5,7,8].
Sudlow and Carter conducted studies that proved specific sites in the human serum albu-
min structure bind to drugs—binding sites I and II [7,9–11]. The first binding site, called the
warfarin or phenylbutazone binding site, is located in subdomain IIA. The typical ligands
for the first binding site are dicarboxylic acids and large, negatively charged heterocyclic
compounds. The second binding site is called the indoles binding site, and the benzo-
diazepines binding site is located in subdomain IIIA. The typical ligands for the second
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binding site are aromatic carboxylic acids with ionized COO− group outlying from their
hydrophobic center, for example, non-steroidal anti-inflammatory drugs [1,7,9–12].
In this work, an analysis was performed of the conformational changes of human
serum albumin caused by interaction with ibuprofen in the presence and absence of
fatty acids.
Ibuprofen ((RS)-2-(4-(2-methylpropyl) phenyl) propanoic acid, IBU) is a non-steroidal
anti-inflammatory drug (NSAIDs) belonging to the group of propionic acid derivatives.
Ibuprofen is the most widely used over-the-counter non-steroidal anti-inflammatory
drug [13,14]. Ibuprofen belongs to a nonselective cyclooxygenase enzyme (COX) inhibitor.
It takes part in inhibiting the cyclooxygenase enzymes COX-1 and COX-2 [15]. Ibuprofen
exhibiting a high affinity for plasma proteins. The primary binding sites for ibuprofen
in the HSA are found in subdomain IIA, IIB, and IIIA [13]. According to the Food and
Drug Administration (FDA) recommendations, ibuprofen can be used to treat migraine
pain, sore throat, pain caused by colds or flu, rheumatoid disorders, inflammatory diseases,
muscle sprains, or strains, joint aches. Ibuprofen is also indicated as an antipyretic, used for
fever reduction in both adults and children [16,17].
Fatty acids (FA) play an important role in the human body’s energy metabolism
but are not soluble in aqueous solutions, for example, in blood plasma and interstitial
fluids. To increase fatty acids concentration in vascular and interstitial compartments is
need binding protein such as albumin, which binds fatty acids in extracellular fluids [18].
The tertiary structure of HSA and its interaction with fatty acids have been studied over the
past decades using X-ray crystallography and NMR spectroscopy [19]. The affinity of fatty
acids to albumin depends on the chemical structure of fatty acids, e.g., on the length of the
chain and the position of the double bonds in the case of unsaturated acids [20]. The crystal
structure of the SA-FAs complex showed that fatty acids bind at seven binding sites in the
tertiary structure of albumin [18,20]. The major binding sites for fatty acids in the human
serum albumin are found in subdomain IB (FA1), IIA (FA7), IIA-IIB (FA6), IIIA (FA3 and
FA4), IIIB, and between domain I and II (FA2) (Scheme 1) [21].
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The fatty acid-binding sites shown in the diagram (Scheme 1) bind medium-chain,
long-chain, monounsaturated, and also polyunsaturated fatty acids [23]. As a result
of the interaction between fatty acids and the albumin molecule, dramatic changes in
the conformation of the spatial structure of protein occur. There is a significant left-
shift of subdomain I and III in relation to the central subdomain II and rotation of the
side chains of amino acid residues, which has been confirmed by X-ray crystallographic
studies [12]. In consequence, changes in the biological properties of the protein occur.
Similar conclusions were made by Yamasaki in his study on the influence of long-chain
fatty acids on the ligand binding interaction at two main drug binding sites (drug sites
I and II) in human serum albumin. Their results indicate that the fatty acids present in
human serum albumin not only contribute to changing the conformation of the protein
structure but also modify individual ligand binding to albumin and interaction between
the ligands [24].
Competition between ligands such as drugs and fatty acids is unlikely. Still, the fatty
acids can occupy several binding sites in the tertiary structure of albumin and cause insta-
bility in the drug-protein complex. In the case of IBU–HSA and IBU–dHSA interactions,
fatty acids may compete with ibuprofen for the binding site IIIA and IIA-IIB. Therefore the
most important aspect of research is estimating the binding parameters for a drug-albumin
complex, which provides information on changes in protein-drug affinity in the presence
of fatty acids in the temperature range of 308–314 K [25–27]. The temperature of 308 K is
the temperature close to the extreme therapeutic value of hypothermia (307 K) used in
clinical conditions [28]. The temperature of 310 K is the temperature corresponding to
physiological conditions. The temperature of 312 K and 314 K correspond to inflammation
in the human body.
The aim of our research was to show the influence of the presence of fatty acids on
changes in the concentration of the free drug fraction, which is of significant pharmacologi-
cal importance. The combination of research techniques such as circular dichroism and
spectrofluorescence allowed the identification of significant differences in drug binding to
serum albumin.
2. Materials and Methods
2.1. Chemicals
Fatted and defatted human serum albumin (HSA and dHSA) fraction V were obtained
from MP Biomedicals LLC (Illkirch, France). Ibuprofen (IBU), sodium dihydrogen phos-
phate (Na2HPO4), dipotassium phosphate (K2HPO4), and methanol were purchased from
Sigma-Aldrich Chemical Co. (Darmstadt, Germany). All reagents and solvents were of the
highest analytical quality.
2.2. Solutions and Sample Preparation
A 0.05 M phosphate-buffered saline solution (PBS) at pH 7.4 was prepared by dis-
solving 3.4836 g of K2HPO4 and 0.6000 g of NaH2PO4 with the appropriate amount of
distilled water. For human serum albumin-ibuprofen interaction analysis, a stock solution
of ibuprofen at 1.5 × 10−2 M concentration was prepared in methanol. The methanol
content in the samples did not exceed 1% of the tested protein solution total volume. Fatted
(HSA) and defatted (dHSA) human serum albumin at the concentration of 5 × 10−6 M
were prepared in a phosphate buffer solution.
2.3. Fluorescence and the UV-VIS Spectra
The fluorescence and absorbance measurements of the samples were recorded in
the temperature range between 308 K and 314 K and pH albumin solution 7.4. For the
measurement standards, quartz cuvettes 1 cm × 1 cm × 4 cm were used. To obtain the
complex IBU–HSA and IBU–dHSA, the fatted and defatted human serum albumin solution
(5 × 10−6 M) was titrated directly into the cuvette by the addition of increasing aliquots of
IBU stock solution (1.5 × 10−2 M).
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Absorption spectra were recorded on spectrophotometer LAMBDA BIO 40 Perkin-
Elmer in the wavelength range between 250–400 nm. Correcting error of the apparatus was
equal to ±0.3 nm and ±0.002 Abs. at 0.5 Abs for wavelength and photometric, respectively.
Absorption of second derivative spectra using the Savitzky and Golay algorithm, second-
order polynomial, and 15 data points were obtained using the UV WinLab program.
The fluorescence emission spectra were recorded on fluorescence spectrophotometer
JASCO FP-6300 (Jasco International Co., Ltd., Tokyo, Japan) equipped with a Peltier
thermostat (∆T ± 0.2 ◦C). The correcting error of the apparatus was equal to ±1.5 nm.
The fluorescence emission spectra were collected in the wavelength range of 285–450 nm
for λex 275 nm (exites tyrosyls and tryptophanyl residues) and 305–450 nm for λex 295 nm
(excites tryptophanyl residue). Light scattering caused by phosphate buffer was subtracted
from the fluorescence of analyzed samples using the JASCO (Spectra Manager) software.
The intensity of fluorescence was corrected for the inner filter effect [29], and then the
obtained spectra were analyzed using OriginPro version 8.5.0 SR1 software (Northampton,
MA, USA). The study results were presented as a mean ± relative standard deviation (RSD)
which were determined from three independent experiments.
Based on fluorescence data, the fluorescence curves of human serum albumin (HSA and
dHSA) in the presence of ibuprofen (IBU) have been plotted. The Stern–Volmer (KSV) and
association (Ka) constants have been determined to analyze the interactions between
ibuprofen and fatted and defatted human serum albumin.
The Stern–Volmer constants KSV were calculated using the Stern–Volmer equation
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where n is the number of binding sites in the albumin molecule; [Lf] is the free drug
concentration; r is the number of ligands bound to one protein molecule.
To determine the association, Ka and interaction coefficients were used in the Hill






= nH· log[Lf] + log Ka (3)
where nH is Hill’s coefficient.
2.4. Circular Dichroism
Circular dichroism (CD) is an absorption spectroscopy method based on the differential
absorption of left and right circularly polarized light [34]. The CD spectra of 5 × 10−6 M
fatted and defatted human serum albumin in phosphate buffer (pH 7.4) were performed
using a Jasco model J-815 spectropolarimeter (Hachioji, Tokyo, Japan) equipped with
a Peltier cell holder with an accuracy of ±0.05 ◦C. Circular dichroism measurements
were made in a nitrogen atmosphere at a temperature range between 308 K and 314 K
in a 1 mm path-length quartz cuvette. The spectra were recorded in the wavelength
range of 200 nm to 250 nm. The CD spectrum of far-ultraviolet (far-UV CD) proteins
below 250 nm reflects the secondary structure of the protein, i.e., the α-helical structure,
β-sheet, β-turn, and unstructured elements. The correcting error of the apparatus was
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equal to ±0.1 nm for the wavelength measurement, and the wavelength repeatability was
±0.05 nm. To reduce random error and noise, each measured spectrum was the average of
three different measures taken under identical conditions and corrected for the buffer’s
absorbance. Then using Savitzky and Golay method, obtained spectra were smoothed.
The observed ellipticity (θobs) was converted to the Mean Residue Ellipticity (θMRE) in deg





where θobs is observed ellipticity for a given wavelength (deg), MRW is a mean residue
weight (MRWHSA = 113.7 Da), l is the path length of the cuvette (cm) and Cp is the protein
concentration (g/cm3).
2.5. Statistical Analysis
In this work, all experiments and measurements were carried out in triplicate, and data
were expressed as a mean ± standard deviation (SD). The resulting data were analyzed
using OriginPro 8.5.0 SR1 (OriginLab Corporation, Northampton, MA, USA).
3. Results and Discussion
Spectroscopic analysis (spectrophotometry, spectrofluorimetry, and circular dichroism)
of ibuprofen interactions with human serum albumin.
3.1. The UV-VIS Analysis of Effect of Fatty Acids and Temperature on the Binding of Human
Serum Albumin with Ibuprofen
The UV-VIS absorption spectroscopy technique was used to determine the structural
changes of fatted (HSA) and defatted (dHSA) human serum albumin under the influence
of ibuprofen [35,36].
Figure 1 shows the UV-VIS human serum albumin (HSA and dHSA) spectra at various
temperature conditions.
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Figure 1. The spectrophotometric spectra of fatty (a) and defatted (b) human serum albumin (5 × 10−6 M) at 308 K, 310 K,
312 K, and 314 K.
The HSA and dHSA UV-VIS spectrum in the wavelength range of 250–305 nm shows
the absorption spectrum of aromatic amino acids (tryptophanyl, tyrosyl residues, and
phenylalanine) present in the protein structure. Based on the results, it was found that
in the case of defatted human serum albumin, the temperature changes in the range of
308–314 K did not significantly change the value of protein absorbance. In the case of fatty
human serum albumin at 308 K and 310 K, the HSA absorbance is the same. However,
an increase in the temperature influences changes in the tertiary structure of albumin.
Based on the spectrophotometric spectra of fatted human serum albumin (Figure 1a),
it was found that at the temperature of 312 K and 314 K, baseline drift occurred. Baseline
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drift is a commonly encountered problem. It is difficult to avoid this problem during the
measurements due to the many parameters associated with it. This may be due to the
occurrence of solution opacity when increasing the temperature. The fatty acid system
with human serum albumin is not very stable. Fatty acids can leave the binding site at
higher temperatures, with the consequent formation of micelles and the turbidity of the
solution [37].
Figure 2 shows the first-order derivative of fatted and defatted human serum albumin
with and without ibuprofen in the temperature range 308–314 K.
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Figure 2. The spectrophoto etric spectra of fatty (–) and defatty (–) hu an seru albu in (5 × 10−6 M) at concentrations
of ibuprofen 1 × 10−4 M (do ted line) at the temperatures: T = 308 K (a); T = 310 K (b); T = 312 K (c); T = 314 K (d).
Based on the obtained human serum albumin UV-VIS spectra presented in Figure 1,
at temperatures of 308 K, the absorbance of HSA is higher than dHSA; however, at temper-
atures of 310 K, the opposite situation occurred, AbsHS < AbsdHSA. Moreover, the spec-
trophotometric analysis showed that the absorbance value of the fatted and defatted
albumin at 312 K and 314 K was the same.
By analyzing the ibuprofen-human serum albumin complex at the temperature range
of 308–314 K, it was found that the drug after binding HSA and dHSA (at 308 K, 312 K,
and 314 K) did not significantly affect the tertiary structure of blood serum albumin from
the spectrophotometric point of view. On the other hand, at the temperature of 310 K,
the absorbance of fatted and defatted albumin after binding with ibuprofen increased
significantly. This proves that the presence of fatty acids has no influence on the interaction
between the protein and the drug at the temperature corresponding to physiological
conditions.
Figure 3 shows the second derivatives of the human serum albumin (HSA and dHSA)
spectrum with and without ibuprofen at different albumin temperatures.
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Figure 3. The second derivative absorption spectra of fatty (–) and defatty (–) human serum albumin (5 × 10−6 ) at
t ti s of ibuprofen 1 × 10−4 (dotted line) t temperatures: T = 308 K (a); T = 310 K (b); T = 312 K (c); T = 314 K (d).
The second derivative of the UV-VIS spectrum, expressed as the wavelength depen-
dence of d2A/dλ2, provides detailed information on changes in the tertiary structure of
human serum albumin that may be invisible or faintly visible first-order absorption spec-
trum [38–40]. The spectral range of 250–270 nm describes changes within phenylalanine
residues (Phe) in the protein structure. The wavelength range 270–293 nm is characteristic
of the tyrosyl residues (Tyr) and tryptophanyl residue (Trp-214) in HSA, while the range of
293–305 nm describes only the tryptophanyl residue (Trp-214) of the protein.
Based on the obtained results, it was observed that in the analyzed temperature range,
the most significant differences between the fatted and defatted human serum albumin
occur in the wavelength range corresponding to the tyrosyl and tryptophanyl residues of
albumin (285 nm and 295 nm). Comparing the spectra of pure protein and the drug-protein
complex, it was found that the presence of ibuprofen influences the tertiary structure of
albumin around the tryptophanyl residues (295 nm). The presence of ibuprofen lowers the
d2A/dλ2 value in the wavelength range of 293–297 nm.
3.2. The Fluorescence Analysis of Effect of Fatty Acids and Temperature on the Binding of Human
Serum Albumin to Ibuprofen
The spectrofluorometric analysis provides information on changes of the hydrophobic
surrounding of the tryptophanyl and tyrosyl residues in serum albumin in the presence
of drugs. The ibuprofen-human serum albumin systems were excited by radiation with
wavelengths of λex 275 nm (excitation of tryptophanyl and tyrosyl residues of human
serum albumin) and λex 295 nm (excitation of tryptophanyl residues of (d)HSA) [7,29,41].
Additionally, a differential spectrum was created for the protein-bound with the drug that
charted serum albumin’s tyrosyl residues.
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Based on the emissive fluorescent spectra of the IBU–HSA system (data not shown),
when the IBU–HSA system was excited by radiation of wavelengths, λex 275 nm and λex
295 nm, the fluorescence of fatty and defatted albumin increased with increasing ibuprofen
concentrations at all studied temperatures.
Figure 4 shows fluorophore fluorescence quenching curves of fatted human serum
albumin (HSA) and defatted human serum albumin (dHSA) bound with ibuprofen (IBU)
in the temperature range 308–314 K.
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Figure 4. Fluorescence intensification curves of fatty () and defatted (•) human serum albumin (5 × 10−6 M) at various
concentrations of ibuprofen (1 × 10−5–1 × 10−4 M) at (a) 308 K, (b) 310 K, (c) 312 K, and (d) 314 K; λex 275 nm and λex
295 nm (in insert).
By comparing the fluorescence intensification curves of HSA and dHSA in the pres-
ence of IBU by exciting the system with radiation of wavelength λex 275 nm and λex 295 nm
was observed differences in their course. More intense excitation of the protein fluorescence
occurs when the IBU–SA complex is exposed to radiation with a wavelength of λex 295 nm.
This phenomenon indicates the participation of tryptophanyl residues located in subdo-
main IIA (Trp-214) as well as tyrosyl group residues localized in subdomains IB (Tyr-138,
Tyr-140, Tyr-148, Tyr-150, and Tyr-161), IIB (Tyr-319, Tyr-332, Tyr-334, Tyr-341, Tyr-353,
and Tyr-370), IIA (Tyr-263), and IIIA (Tyr-401, Tyr-411, Tyr-452, and Tyr-497) [7,29,41].
Similar research was carried out by Amézqueta in his study evaluating the interactions
between human serum albumin and non-steroidal anti-inflammatory drugs by multiwave-
length molecular fluorescence, structural and computational analysis. The results showed
slight changes in the spectra of human serum albumin under the influence of ibuprofen.
The author reported the increase in HSA fluorescence after ibuprofen binding [42].
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Moreover, when analyzing the fluorescence intensification curves of serum albumin,
it was found that ibuprofen more strongly enhances the fluorophore fluorescence of fatted
human serum albumin, exciting the IBU–HSA system with radiation with wavelengths
of λex 275 nm, compared to defatted albumin. By exciting the IBU-SA complex with the
radiation of wavelength λex 295 nm, it was observed that at the temperature of 308 K and
310 K, the course of the fluorescence intensification curves of the serum albumin fluo-
rophores was the same. At a temperature of 312 K above the IBU, SA molar ratio of 14:1,
and at a temperature of 314 K above 7:1, it was found that fatty albumin weakly enhanced
the fluorescence of protein fluorophores compared to defatted albumin. Analyzing the
influence of temperature on ibuprofen binding by human serum albumin, it was found
that with the increase in the measurement temperature, the percentage of fluorescence
fluorophores intensity of both albumins (HSA and dHSA), excited with the wavelength
of λex 275 nm and λex 295 nm increases. Based on the results obtained, it could be con-
cluded that by interacting with the human serum albumin molecule, ibuprofen breaks the
tryptophan-tryptophan hydrogen bonds, which increases the number of free tryptophan
molecules in the system, causing an increase in the tryptophanyl residue fluorescence [43].
To determine the contribution of tyrosyl residues in the IBU-HSA bond, a differential
spectrum was created for the HSA and dHSA bound with ibuprofen, as shown in Figure 5).
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Figure 5. Fluorescence quenching curves of tyrosine in fatty () and defatted (•) human serum albumin (5 × 10−6 ) at
vari us concentrations of ibuprofen (1 × 0−5–1 × 10−4 M) at (a) 308 K, (b) 310 K, (c) 312 K, and (d) 314 K.
Based on the presented fluorescence quenching curves of tyrosyl residues in fatty and
defatted human serum albumin under the influence of ibuprofen, it was observed that
an increase in the concentration of the drug causes a more substantial quenching of the
fluorescence of tyrosyl residues in the albumin molecule. In addition, at a temperature of
308 K, fluorescence quenching of tyrosyl residues in a protein is independent of the presence
of fatty acids. In the temperature range of 310–314 K, it was found that defatted human
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serum albumin quenches the fluorescence of tyrosyl residues more strongly than fatty
albumin above the molar ratio IBU: SA 7:1 at a temperature of 310 K and 2:1 at 312 K and
314 K. Additionally, a linear relationship was observed between the degree of fluorescence
quenching of defatted albumin tyrosyl residues and temperature. This relationship was
not observed in the case of fatty albumin [44].
On the basis of the obtained results, it was found that the formation of the IBU–SA
complex mainly involved protein tyrosyl residues located in the IB subdomain (Tyr-138,
Tyr-140, Tyr-148, Tyr-150, and Tyr-161), IIB (Tyr- 319, Tyr-332, Tyr-334, Tyr-341, Tyr-353,
and Tyr-370), IIA (Tyr-263), and IIIA (Tyr-401, Tyr-411, Tyr-452, and Tyr-497), which was
confirmed by Ghuman in his work concerning specific places of drug binding with serum
albumin [21,29,41]. By analyzing the crystallography of 17 different SA complexes with
various drugs, including ibuprofen, Ghuman determined the precise architecture of drug
binding in the protein at two major binding sites [21]. Evoli, in their work, also showed
the graphically binding of ibuprofen to serum albumin by using absolute binding free
energy calculations in combination with classical molecular dynamics simulations and
the molecular docking of ibuprofen for albumin. On the basis of the conducted analyzes,
they found that the most favorable binding location for ibuprofen in the human serum
albumin structure was the DS2 (IIIA subdomain) binding site. The second preferred
binding site found in the simulation was DS1 (IIA subdomain). The binding site DS1 was
characteristic of warfarin. When an excess of ibuprofen had saturated its primary site
DS2, warfarin can be displaced from the DS1 site in albumin under excess of ibuprofen.
On the basis of simulations, Evoli concluded that the DS1 position is little described in
the literature due to the multiple ways of creating bonds between ibuprofen and albumin
compared with site FA6 (IIA-IIB subdomain), although the FA6 site is found only as a
secondary site. Additionally, the FA6 and FA2 sites have been described as sites with a
less favorable affinity for albumin. FA1 (IB subdomain) and FA5 (IIIB subdomain) sites
are low-affinity ibuprofen binding locations but can bind ibuprofen under opportune
conditions but with very low affinity [45]. Although studies on the molecular dynamics of
human serum albumin are available in the literature, it is difficult to observe the effect of
temperature on them.
Based on the modified Stern-Volmer curves (data not shown), linear regression curves
were drawn, then used to determine the Stern–Volmer constants for the IBU–SA complex
in the temperature range 308–314 K (Table 1).
Table 1. Stern-Volmer constants KSV (M−1) were calculated for IBU–SA systems.
KSV (M−1) ± SD × 10−4 (M−1)
λex 275 nm λex 295 nm Tyr
308 K
HSA 2.83 ± 0.04 0.73 ± 0.11 0.23 ± 0.12
dHSA 4.09 ± 0.13 1.48 ± 0.01 0.83 ± 0.03
310 K
HSA 3.10 ± 0.08 0.88 ± 0.05 0.33 ± 0.09
dHSA 5.05 ± 0.48 1.24 ± 0.02 0.51 ± 0.07
312 K
HSA 3.95 ± 0.11 0.87 ± 0.06 0.38 ± 0.06
dHSA 5.02 ± 0.47 1.27 ± 0.02 0.47 ± 0.07
314 K
HSA 4.76 ± 0.17 1.26 ± 0.04 0.53 ± 0.12
dHSA 6.71 ± 0.17 1.66 ± 0.01 0.57 ± 0.05
SD: Standard deviation.
Based on the presented Stern-Volmer constant values, it may be stated that when
exciting the IBU-HSA system with radiation with wavelengths of λex 275 and λex 295 nm,
the KSV constants of dHSA are higher compared to HSA. Additionally, the Stern-Volmer
constants of both HSA and dHSA increase with increasing temperature. The same is the
case with the KSV values determined for the differential modified Stern–Volmer curves.
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The Stern–Volmer constant allows for determining the fluorophores availability for the
ligand, characterizing the distance between the ligand and the excited protein fluorophore.
Increasing the values of the Stern–Volmer constant KSV indicates that the ligand is closer
to the protein, which contributes to the formation of the protein-ligand complex, and the
stronger the complex (higher KSV value), the weaker the therapeutic effect [46]. The ob-
tained results indicate that stronger complexes were formed with increasing tempera-
ture, which means a lower therapeutic effect. Peng made similar conclusions in the
study concerning the interaction between coenzyme Q10 and human serum albumin
and Hashempour in analyzing the interaction between HSA and 5-aminoimidazole-4-
carboxamide ribonucleoside [3,47]. They observed that the KSV value increases with
temperature. On the other hand, the presence of fatty acids in the albumin molecule
increases the therapeutic effect compared to defatted albumin.
Based on data collected from emissive fluorescent spectra, Klotz plots and Hill plots
(data not shown) were created to determine the Ka association constants, the number of
binding sites in the IBU–SA system, and the Hill coefficient values (nH) (Table 2).
Table 2. Association constants Ka (M−1), mean number of IBU moles bound with one mole of SA (n),
and the Hill’s coefficient (nH) in the IBU-SA system.
Klotz Method Hill Method
Ka (M−1) ± SD × 10−4 (M−1)
n ± SD
Ka (M−1) ± SD × 10−4 (M−1)
nH ± SD
λex 275 nm HSA dHSA HSA dHSA
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Analyzing the obtained values of the association constants determined by the Klotz
and Hill method, it was found that by exciting the IBU-SA system with radiation with a
wavelength of λex 275 nm and λex 295 nm and based on differential spectra, the association
constant Ka for defatted albumin was higher than the Ka for fatty albumin. Moreover,
by inducing both tyrosyl and tryptophanyl residues of the protein, it was observed that the
constant association value of the dHSA increased with increasing temperature. This rela-
tionship was not noted for fatty albumin. In the case of excitation of only tyrosyl residues,
no dependence of the association constant on temperature was observed. The obtained
values of Ka (Table 2) and KSV (Table 1) allow us to suppose that the complexes of the tested
IBU are more stable with the defatted human serum albumin than with the fatted protein.
The number of binding sites n describes the number of ligand molecules per protein
molecule. Based on the obtained values determined from the Klotz curves, the highest
affinity of ibuprofen to fatty and defatted albumin fluorophores was observed at the
temperature of 308 K (λex 295 nm) and the temperature of 314 K (λex 275 nm) in the case of
fatty albumin.
A similar relationship between the value of the association constants and the presence
or absence of fatty acids in albumin was observed in the study of Varshney. The author
observed an approximately five-fold decrease in the value of the association constant of
fatty albumin in comparison with the protein without fatty acids. In addition, Varshney
found that the number of n binding sites remained almost unchanged in the analyzed
complex human serum albumin–hemin (probe for monitoring the effect of fatty acid on
the binding properties of domain I), indicating reduced stability of the fatted HSA-hemin
complex compared to the fatty acid-free HSA-hemin complex. These results suggest that
the fatty acid affects I domain binding [48].
Describing the relationship between the drug and the protein Hill constants (nH)
values were determined. For nH = 1, the binding of the ligand to the protein molecule was
non-cooperative. For nH > 1 there is a positive, cooperative relationship. Binding the ligand
in one place increases the affinity of the ligand to the rest of the macromolecule binding
sites. For nH < 1 means a reduction in the relationship of the ligands to the following
binding site [33]. By exciting the IBU-SA system with radiation with a wavelength of λex
275 nm, the values of Hill’s constant are comparable for fatty and defatted albumin and
were in the range 0.80 ± 0.12–0.84 ± 0.08 for HSA and 0.82 ± 0.10–0.90 ±0.12 for dHSA.
This proved a negative coherent bond between the protein tryptophanyl residues and
ibuprofen and weakening the bonding in the second-class binding site. The same results
can be seen at the temperature range of 308–314 K for HSA and 310 K, 314 K for dHSA by
exciting the IBU-SA system with radiation with a wavelength of λex 295 nm. By exciting
only the tyrosyl residues of HSA and dHSA in the analyzed temperature range, a positive
cooperative relationship occurred; the binding of the ligand in one site increased its affinity
to other protein binding sites [49].
3.3. The Circular Dichroism Analysis of Effect of Fatty Acids and Temperature on the Binding of
Human Serum Albumin with Ibuprofen
Using the circular dichroism technique was possible to analyze the changes in the
secondary structure of the protein under the influence of fatty acids and drugs in the
temperature range of 308–314 K. CD spectra of fatty and defatted human serum albumin
and complexes IBU-HSA and IBU-dHSA are presented in Figure 6.
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Figure 6. CD spectra of fatty (–) and defatted (–) human serum albumin (5 × 10−6 M) at concentrations of ibuprofen
1 × 10−4 M (dotted line) at temperatures: T = 308 K (a), T = 310 K (b), T = 312 K (c), and T = 314 K (d).
Based on the spectra obtained, it was observed that both defatted and fatted human
serum albumin were α-helical proteins. There are two characteristic minima in the CD
spectrum at λmin 210 nm and λmin 221 nm [50,51]. The observed ellipticity of the defatted
protein was higher compared to that of the fatty protein. Moreover, under the influence of
ibuprofen, the observed ellipticity increased in the analyzed temperature range, and the
band shifted from λmin 221 nm to λmin 220 nm.
Based on the observed ellipticity and Equation (4) values, the value of the mean
ellipticity θMRE was calculated for fatty albumin, defatted albumin, IBU–HSA, and IBU–
dHSA complexes. The results are shown in Table 3.
Based on the obtained results presented in Table 3, it was observed that the value
of θMRE was higher for defatted albumin compared to fatty albumin in the analyzed
temperature range. At the wavelength λmin 210 nm, the value of the mean ellipticity of
dHSA was 0.96 times higher than for HSA, while for λmin 221 nm, the value of θMRE
dHSA was 0.94 times higher than that of HSA. The β-type proteins are characterized by
the presence of only one negative band around λmin 220 nm [50,51]. This slightly weaker
increase in the mean residue ellipticity for the λmin 221 nm band may indicate an increase
in the content of α-helical structures and a decrease in the β-structural elements in defatted
human serum albumin compared to fatty albumin.
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dHSA 210 −19,921.64 221 −18,349.67
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Analyzing the influence of ibuprofen on the secondary structure of human serum
albumin, it was found that in the studied temperature range, the value of θMRE was higher
for human serum albumin bound to ibuprofen compared to pure albumin (HSA and dHSA).
Analyzing the values at the negative band around λmin 210 nm, it was found that for the
IBU-dHSA complex, the θMRE values were 0.970–0.975 times greater than for dHSA, and for
IBU-HSA, 0.934–0.941 times greater than for HSA. Additionally, it was observed that there
was a shift of the minimum of the second negative band under the influence of ibuprofen
from λmin 221 nm to λmin 220 nm. Analyzing the values of θMRE in the second negative
band, it was found that for the complex IBU–dHSA θMRE value was 0.980–0.989 times
higher than for dHSA, and for IBU–HSA 0.929–0.941 times higher than for HSA in the
temperature range 308–314 K. This slightly stronger increase in the mean residues ellipticity
for the λmin 221 nm in albumin devoid of fatty acids may indicate a decrease in the content
of α-helical structures and an increase in β-structural elements. HSA probably changes
from the native state characterized by two minima to a spectrum with a visible minimum
and less visible second one as a consequence of β-sheet structure, absent in unmodified
protein [52]. On the other hand, when analyzing the θMRE values of fatty protein, it was
found that the presence of fatty acids contributes to an increase in the content of α-helical
structures and a decrease in β- structural elements.
Using the secondary structure evaluation program with the Yang reference model,
the predicted changes in the protein α-helical structure confirmed a β-sheet conformation
(Table 4).
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Table 4. The percentage (%) content of the secondary structure elements of 5 × 10−6 M serum
albumin in the temperature range 308–314 K. Yang’s reference model.
% α—Helix % β—Sheet % Other
308 K
HSA 55.6 9.2 35.1
IBU-HSA 59.0 1.2 39.9
dHSA 58.7 1.8 39.5
IBU-dHSA 56.1 8.5 35.4
310 K
HSA 55.8 8.7 35.4
IBU-HSA 59.0 1.7 39.3
dHSA 58.8 1.8 39.4
IBU-dHSA 56.5 8.0 35.6
312 K
HSA 55.9 8.3 35.8
IBU-HSA 58.9 1.4 39.7
dHSA 59.1 1.3 39.5
IBU-dHSA 56.6 8.1 35.3
314 K
HSA 56.1 8.0 35.9
IBU-HSA 58.9 1.1 40.0
dHSA 59.1 1.2 39.8
IBU-dHSA 56.7 7.0 36.3
Based on the data presented in Table 4, changes in the proportions between the
structure of the α-helix and the β-sheet of human serum albumin under the influence of
ibuprofen and fatty acids in the analyzed temperature range were observed. The process
of structural modification is regulated by several factors, including temperature, protein
concentration, pH, presence of drugs, electrolytes, metal ions, degree of irradiation, etc. [53].
However, in this case, the presence of ibuprofen and fatty acids played the greatest role.
Temperature changes did not significantly change the percentage of secondary structural
elements in the human serum albumin structure. The circular dichroism measurements
carried out by Yamasaki also confirmed the influence of fatty acids on the modification of
the spatial structure of albumin. Additionally, a change in the spatial orientation of the
ligand at its binding site was observed [24].
4. Conclusions
The conducted research for fatted and defatted human serum albumin and their com-
plex with ibuprofen allowed us to obtain promising conclusions about the influence of
fatty acids and temperature on the binding of drugs to serum albumin. The affinity of
ibuprofen to human serum albumin, as well as changes in the concentration of the free
drug fraction and the protein-bound fraction, are very important from a pharmacological
point of view. Only the non-protein-bound form of the drug is pharmacologically active.
The remaining fraction, bound to protein, serves as a depot of the drug in the body. On the
other hand, fatty acids occupy certain characteristic places in the structure of albumin,
which contributes to the destabilization of the drug-protein complex. The knowledge of the
ibuprofen binding site in the albumin molecule, as well as the possibility of competition
between ibuprofen and fatty acids, affects the concentration of the free drug fraction in the
bloodstream, and thus its therapeutic effect. In addition, the increased content of fatty acids
in the body affects the pharmacokinetics of the drug. Therefore, a very important aspect of
the study was to assess the effect of fatty acids on the affinity of ibuprofen for albumin at
temperatures close to the extreme value of hypothermia (T = 308 K), at the temperature
corresponding to physiological conditions (T = 310 K) and at temperature correspond to
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inflammation in the human body (T = 312 K and 314 K). Fluorescence spectroscopy is a tech-
nique that allows the monitoring of intermolecular interactions. In order to observe how
the protein secondary and tertiary structure changes, far-UV CD spectroscopy and UV-VIS
absorption spectroscopy were used, respectively. The results obtained using spectroscopic
techniques showed that the presence of fatty acids disturbs the binding of ibuprofen to
human serum albumin. Based on the spectrophotometric analysis, it was found that fatty
acids and temperatures of human serum albumin affected the structural change in the area
of albumin tryptophanyl and/or tyrosyl groups was observed at the analyzed temperature
range, which was confirmed by the results obtained from the spectrofluorimetric analy-
sis. On the basis of the obtained results, it was found that the formation of the IBU-SA
complex mainly involves protein tyrosyl residues independent of the presence of fatty
acids and temperature. The obtained results indicate that stronger complexes are formed
with increasing temperature, which means a lower therapeutic effect. On the other hand,
the presence of fatty acids in the albumin molecule increases the therapeutic effect com-
pared to defatted albumin. Ibuprofen, therefore, releases from the IBU-dHSA complex
more slowly, exhibiting a longer but weaker effect. Additionally, the increase in the Stern–
Volmer constant with increasing temperature indicates the involved binding forces are
probably mainly hydrophobic interactions [22]. Based on the CD spectra, changes in the
proportions between the structure of the α-helix and the β-sheet of human serum albumin
under the influence of ibuprofen and fatty acids in the analyzed temperature range were
observed. In the structural modification process, the presence of ibuprofen and fatty acids
played the greatest role. Temperature changes did not significantly change the percentage
of secondary structural elements in the human serum albumin structure. Based on the
analysis, it was observed that HSA probably changes from the native state characterized
by two minima to a spectrum with a visible minimum and less visible second one as a
consequence of β-sheet structure, absent in unmodified SA. Ibuprofen binds more strongly
to defatted protein (dHSA) than to albumin in the presence of fatty acids (HSA), and the
competitive binding of ibuprofen and fatty acids to albumin influence the concentration of
free drug fraction and its therapeutic effect. The conformational changes in the structure of
the human serum albumin molecule affect its ability to bind ligands.
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